Arrowhead Pharmaceuticals (NASDAQ:ARWR) PT Lowered to $27.00 at Morgan Stanley
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price lowered by Morgan Stanley from $36.00 to $27.00 in a research report report published on Monday morning, Benzinga reports. The brokerage currently has an equal weight rating on the biotechnology company’s stock. A number of other equities research analysts have also recently weighed in on […]
More Stories
Youdao (NYSE:DAO) Trading 7.6% Higher – What’s Next?
Youdao, Inc. (NYSE:DAO – Get Free Report)’s stock price shot up 7.6% on Tuesday . The stock traded as high...
Valaris (NYSE:VAL) Sets New 12-Month Low – Should You Sell?
Valaris Limited (NYSE:VAL – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Tuesday ....
Schwab U.S. Large-Cap Growth ETF (NYSEARCA:SCHG) Reaches New 1-Year High – Time to Buy?
Shares of Schwab U.S. Large-Cap Growth ETF (NYSEARCA:SCHG – Get Free Report) hit a new 52-week high during trading on...
MicroSectors Energy 3X Leveraged ETN (NYSEARCA:WTIU) Sees Large Volume Increase – What’s Next?
MicroSectors Energy 3X Leveraged ETN (NYSEARCA:WTIU – Get Free Report) saw strong trading volume on Tuesday . 81,878 shares were...
Hive Price Reaches $0.18 on Major Exchanges (HIVE)
Hive (HIVE) traded down 3.8% against the U.S. dollar during the one day period ending at 19:00 PM E.T. on...
Sabra Health Care REIT (NASDAQ:SBRA) Sets New 52-Week High – Still a Buy?
Sabra Health Care REIT, Inc. (NASDAQ:SBRA – Get Free Report)’s stock price hit a new 52-week high during trading on...